NEW YORK (360Dx) – Breathalyzer-based diagnostic firm Owlstone Medical today said it has raised approximately $11.6 million in an investment round.

Existing investors participated in the round, which will go toward a commercial launch of Owlstone's breath biomarker R&D services, including the opening of a new high-volume clinical facility, the Cambridge, UK-based company said. Funds will also be used for ongoing clinical trials in lung and colon cancer screening.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.